( statedTimothy R. McNamara Pharm.D....)ISTA Pharmaceuticals Announces Statistically Significant,Preliminary Results From its U.S. Phase II/III Clinical Study Of,Bepotastine,Health

" stated Timothy R. McNamara, Pharm.D., ISTA's Vice President, Clinical Research and Medical Affairs. "Should bepotastine's performance in Phase III testing confirm the results we observed in the Phase II/III study, we believe this product, if approved, will have the potential of quickly becoming a favorite amongst physicians and their patients suffering from allergic conjunctivitis."

In the Phase II/III study, there were no serious adverse events reported in patients dosed with bepotastine. Importantly, there were no reports of incidences of burning or stinging with either concentration and no reports of increases in ocular adverse events compared with placebo.

ISTA will host a conference call with a simultaneous webcast today, May 8, 2007 at 10:30 AM Eastern Time to discuss today's announcement regarding the bepotastine Phase II/IIII study preliminary results and other recent product development announcements. To access the live conference call, U.S. and Canadian participants may dial 866-356-4281; international participants may dial 617-597-5395. The access code for the live call is 49242638. To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286- 8010; international participants may dial 617-801-6888. The access code for the replay is 11857565. This conference call will also be webcast live and archived on ISTA's website for 30 days at http://www.istavision.com.

About Bepotastine

Bepotastine for the eye has three primary mechanisms of action: it is a non-sedating, highly selective antagonist of the histamine 1 (H1) receptor, it has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. The compound's primary mechanisms of action are believed to make it an effective treatment against the signs and symptoms of allergic conjunctivitis. According to IMS, in 2006, the U.S. ocular allergic conjunctivitis
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA